Literature DB >> 24462300

The reliability of routine clinical post-processing software in assessing potential diffusion-weighted MRI "biomarkers" in brain metastases.

R Zakaria1, K Das2, M Bhojak2, M Radon2, V Sluming3, C Walker4, M D Jenkinson4.   

Abstract

BACKGROUND AND
PURPOSE: Diffusion MRI characteristics have been used as biomarkers to guide prognosis in cerebral pathologies including brain metastases. The measurement of ADC is often described poorly in clinical and research studies with little detail given to the practical considerations of where to place ROIs, which post processing software package to use and how reproducible the resulting metrics will be.
METHOD: We investigated a series of 12 patients with brain metastases and preoperative DWI. Three post processing platforms were used. ROI were placed over the tumour, peritumoural region and across the brain-tumour interface. These recordings were made by a neurosurgeon and a neuroradiologist. Inter-intra-observer variability was assessed using Bland-Altman analysis. An exploratory analysis of DWI with overall survival and tumour type was made.
RESULTS: There was excellent correlation between the software packages used for all measures including assessing the whole tumour, selective regions with lowest ADC, the change of ADC across the brain-tumour interface and the relation of the tumour ADC to peritumoural regions and the normal white matter. There was no significant inter- or intra-observer variability for repeated readings. There were significant differences in the mean values obtained using different methodologies and different metrics had differing relationships to overall survival and primary tumour of origin.
CONCLUSION: Diffusion weighted MRI metrics offer promise as potential non-invasive biomarkers in brain metastases and a variety of metrics have been shown to be reliably measured using differing platforms and observers.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24462300     DOI: 10.1016/j.mri.2013.12.010

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  4 in total

1.  Diffusion weighted MRI is a promising imaging biomarker in brain metastases.

Authors:  R Zakaria; M D Jenkinson
Journal:  J Neurooncol       Date:  2014-10-30       Impact factor: 4.130

2.  Does the application of diffusion weighted imaging improve the prediction of survival in patients with resected brain metastases? A retrospective multicenter study.

Authors:  Rasheed Zakaria; Yin Jie Chen; David M Hughes; Sumei Wang; Sanjeev Chawla; Harish Poptani; Anna S Berghoff; Matthias Preusser; Michael D Jenkinson; Suyash Mohan
Journal:  Cancer Imaging       Date:  2020-02-07       Impact factor: 3.909

3.  Diffusion-weighted MRI characteristics of the cerebral metastasis to brain boundary predicts patient outcomes.

Authors:  Rasheed Zakaria; Kumar Das; Mark Radon; Maneesh Bhojak; Philip R Rudland; Vanessa Sluming; Michael D Jenkinson
Journal:  BMC Med Imaging       Date:  2014-08-03       Impact factor: 1.930

Review 4.  Diffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumors.

Authors:  Lu Guo; Gang Wang; Yuanming Feng; Tonggang Yu; Yu Guo; Xu Bai; Zhaoxiang Ye
Journal:  Radiat Oncol       Date:  2016-09-21       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.